Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 19/20 | 0.44 |
| ▸ | DDB1 known ✓ | Q16531 | 15/20 | 0.44 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.39 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22720671 | 1.00 | CRBN (0.44) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| Hydrochloric Acid SCHEMBL19347669 | 1.00 | CRBN (0.44) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| Hydrochloric Acid SCHEMBL30144741 | 1.00 | CRBN (0.44) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| Hydrochloric Acid SCHEMBL22720839 | 1.00 | CRBN (0.44) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL528253 | 0.98 | — | — | |
| SCHEMBL5202970 | 0.98 | — | — | |
| SCHEMBL444005 | 0.98 | — | — | |
| Bromide SCHEMBL3545017 | 0.95 | CRBN (0.44) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| Bromide SCHEMBL5203587 | 0.95 | CRBN (0.44) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| Bromide SCHEMBL3546365 | 0.95 | CRBN (0.44) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1984 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836217-B | Preparation and application of PROTAC degradation agent | 中国医学科学院药用植物研究所 | 2026-05-19 | — | — | CN | claimed |
| CN-122010899-A | Continuous flow preparation method of lenalidomide and derivatives thereof | 深圳连续制药科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-116354928-B | Preparation method of 4-bromo-2- (2, 6-dioxopiperidine-3-yl) 7-fluoroisoindoline-1, 3-dione | 南京优氟医药科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-116354929-B | Preparation method of 6-bromo-2- (2, 6-dioxopiperidine-3-yl) 4-fluoroisoindoline-1, 3-dione | 南京优氟医药科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119859137-A | Synthesis method of E3 ubiquitin ligase ligand | 南京优氟医药科技有限公司 | 2025-04-22 | — | — | CN | claimed |
| CN-115557936-B | Preparation method and application of pomalidomide derivative serving as feed additive | 河南湾流生物科技有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-118955474-A | Radioisotope carbon-14 labeled bard-calide and preparation method and application thereof | 浙江爱索拓标记医药科技有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118255743-A | Method for preparing Bai Mite by adopting one-pot method with silica-based protection | 上海奥博生物医药股份有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-118108699-A | Preparation method of lenalidomide | 杭州新曦科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-117417338-A | Novel BRD4 protein targeted degradation agent, and preparation method and application thereof | 中国药科大学 | 2024-01-19 | — | — | CN | claimed |
| WO-2014018866-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | WO | claimed |
| CN-103497174-A | Preparation and refining method of pomalidomide | HANGZHOU PIOPHARM PHARMACEUTICAL TECHNOLOGY CO LTD | 2014-01-08 | — | — | CN | claimed |
| US-20120071509-A1 | PROCESS | TIANISH LABORATORIES PRIVATE LIMITED (IN) | 2012-03-22 | — | — | US | claimed |
| EP-2403845-A2 | IMPROVED PROCESS | Generics [UK] Limited (GB) | 2012-01-11 | — | — | EP | claimed |
| US-20110021567-A1 | PREPARATION OF LENALIDOMIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-01-27 | — | — | US | claimed |
| EP-2262768-A2 | PREPARATION OF LENALIDOMIDE | Dr. Reddy's Laboratories Ltd. (IN) | 2010-12-22 | — | — | EP | claimed |
| WO-2010100476-A2 | IMPROVED PROCESS | GENERICS [UK] LIMITED (GB) | 2010-09-10 | — | — | WO | claimed |
| WO-2009114601-A2 | PREPARATION OF LENALIDOMIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-09-17 | — | — | WO | claimed |
| US-20080064876-A1 | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | CELGENE CORPORATION | 2008-03-13 | — | — | US | claimed |
| WO-2007136640-A2 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE | CELGENE CORPORATION (US) | 2007-11-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071509-A1 | PROCESS | RCC1, FIP1L1, MALT1 | CRBN 54/4885DDB1 1925/4885CHRM2 2092/4885 |
| US-20080064876-A1 | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | TNF, DHPS, IDO1 | CRBN 2874/4885DDB1 3151/4885CHRM2 706/4885 |
| US-20110021567-A1 | PREPARATION OF LENALIDOMIDE | RPS27A, PDCD2L, PML | CRBN 15/4885DDB1 2432/4885CHRM2 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.